Technical Analysis for MTCR - Metacrine, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 5.21 | -0.95% | -0.05 |
MTCR closed down 0.95 percent on Friday, April 9, 2021, on 1.45 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Historical MTCR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -0.95% | |
| Volume Surge | Other | -0.95% | |
| New 52 Week Low | Weakness | -0.95% | |
| Wide Bands | Range Expansion | -0.95% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 1 day ago |
| Up 3% | 1 day ago |
| Up 2% | 1 day ago |
| Up 1% | 1 day ago |
| 1.5x Volume Pace | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Metacrine is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. The company’s most advanced programs, MET409 and MET642, target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. Both MET409 and MET642 are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH).
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Diseases Alcohol Chemical Compounds Gastrointestinal Specialty Drugs Steatohepatitis Hepatitis Non Alcoholic Fatty Liver Disease Gastrointestinal Disease Carboxylic Acids Farnesoid X Receptor Fxr Gi Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Diseases Alcohol Chemical Compounds Gastrointestinal Specialty Drugs Steatohepatitis Hepatitis Non Alcoholic Fatty Liver Disease Gastrointestinal Disease Carboxylic Acids Farnesoid X Receptor Fxr Gi Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.19 |
| 52 Week Low | 5.16 |
| Average Volume | 67,657 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 8.42 |
| 20-Day Moving Average | 6.89 |
| 10-Day Moving Average | 5.93 |
| Average True Range | 0.52 |
| ADX | 40.15 |
| +DI | 10.82 |
| -DI | 36.96 |
| Chandelier Exit (Long, 3 ATRs ) | 8.02 |
| Chandelier Exit (Short, 3 ATRs ) | 6.72 |
| Upper Bollinger Band | 9.05 |
| Lower Bollinger Band | 4.72 |
| Percent B (%b) | 0.11 |
| BandWidth | 62.88 |
| MACD Line | -0.90 |
| MACD Signal Line | -0.76 |
| MACD Histogram | -0.1392 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.65 | ||||
| Resistance 3 (R3) | 5.69 | 5.57 | 5.58 | ||
| Resistance 2 (R2) | 5.57 | 5.46 | 5.55 | 5.55 | |
| Resistance 1 (R1) | 5.39 | 5.39 | 5.33 | 5.36 | 5.53 |
| Pivot Point | 5.28 | 5.28 | 5.25 | 5.26 | 5.28 |
| Support 1 (S1) | 5.10 | 5.16 | 5.04 | 5.06 | 4.89 |
| Support 2 (S2) | 4.98 | 5.09 | 4.96 | 4.87 | |
| Support 3 (S3) | 4.80 | 4.98 | 4.84 | ||
| Support 4 (S4) | 4.77 |
